Literature DB >> 32459534

Updates to Medicare's Quality Payment Program That May Impact You.

Diana M Cardona1, Stephanie Peditto1, Loveleen Singh1, Stephen Black-Schaffer1.   

Abstract

CONTEXT.—: Within Medicare's Quality Payment Program, and more specifically the Merit-based Incentive Payment System, pathologists stand to potentially lose or gain approximately $2 billion during the initial 7 years of the program. If you or your group provides services to Medicare beneficiaries, you will likely need to comply with the program. OBJECTIVE.—: To avoid potential reductions in Medicare reimbursement, pathologists need to understand the requirements of these new payment programs. DATA SOURCES.—: Each year the Centers for Medicare & Medicaid Services publish a Final Rule detailing the program requirements and updates. 2020 marks the fourth reporting year for the Merit-based Incentive Payment System. Performance this year will impact 2022 Medicare Part B distributions by up to ±9%. CONCLUSIONS.—: By staying up to date with the ever-evolving Merit-based Incentive Payment System requirements, pathologists will be better equipped to successfully comply with this relatively new payment system, reduce the burden of participating, understand the reporting differences of the various performance categories, and thereby be able to maximize their scoring and incentive potential.

Year:  2020        PMID: 32459534     DOI: 10.5858/arpa.2019-0376-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  1 in total

1.  Development of quality indicators for the diagnosis and management of achalasia.

Authors:  Afrin N Kamal; Priya Kathpalia; Fouad Otaki; Albert J Bredenoord; Donald O Castell; John O Clarke; Gary W Falk; Ronnie Fass; C Prakash Gyawali; Peter J Kahrilas; Philip O Katz; David A Katzka; John E Pandolfino; Roberto Penagini; Joel E Richter; Sabine Roman; Edoardo Savarino; George Triadafilopoulos; Michael F Vaezi; Marcelo F Vela; David A Leiman
Journal:  Neurogastroenterol Motil       Date:  2021-03-15       Impact factor: 3.960

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.